SynthesisBMC cancer2026
Comparative efficacy of postoperative adjuvant chemoradiotherapy versus no chemoradiotherapy in the treatment of pancreatic adenocarcinoma.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe benefit of adjuvant chemoradiotherapy (CRT) for pancreatic adenocarcinoma (PAAD) is debated. This study aimed to elucidate the impact of adjuvant CRT on survival outcomes.
methodsWe searched major medical databases for clinical and retrospective studies comparing postoperative CRT vs. no CRT in PAAD. Data were synthesized using RevMan 5.4 and Stata 17.0 software. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for overall survival (OS), local recurrence, and distant metastasis.
resultsOur analysis included 19 studies involving 4,581 patients. Adjuvant CRT was associated with a significant improvement in 2-year OS compared to no CRT (OR = 0.63, 95% CI: 0.53-0.76, P < 0.001). This benefit was consistent in subgroup analyses compared to chemotherapy alone (OR = 0.54, P = 0.0003) and the observation group (OR = 0.61, P < 0.001). The 5-year OS analysis showed a non-significant trend favoring CRT (OR = 0.66, 95% CI: 0.43-1.02, P = 0.06). In subgroup analyses, CRT was associated with a significant survival benefit compared with observation alone (OR = 0.67, 95% CI: 0.47-0.97, P = 0.03), but not compared with chemotherapy alone (OR = 0.57, 95% CI: 0.06-5.46, P = 0.62). Notably, patients with high-risk features, including lymph node-positive (2-year OS: OR = 0.47, P < 0.001; 5-year OS: OR = 0.53, P < 0.001) and margin-positive disease (2-year OS: OR = 0.45, P < 0.001), derived substantial survival benefits from CRT. Furthermore, CRT was significantly associated with reduced local recurrence rates (OR = 0.27, P = 0.008) but did not affect the incidence of distant metastasis (OR = 1.11, P = 0.72).
conclusionsThis study shows that adjuvant CRT significantly improves 2-year OS and local tumor control in resected PAAD, especially for patients with lymph node metastasis. However, its effect on long-term (5-year) survival is limited, and it was not associated with distant metastasis. These findings support the selective use of adjuvant CRT for local control in high-risk patient subgroups, such as those with positive lymph nodes or positive surgical margins. Further research is needed to prospectively validate these findings and identify patients most likely to benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.